文献速递眼底病与葡萄膜炎

多基因治疗作为调控新生血管性年龄相关性黄斑变性相关分子表达的工具

Multiple gene therapy as a tool for regulating the expression of molecules involved in neovascular age-related macular degeneration.
PubMed 文献 · Prog Retin Eye Res · 2024-12-11

本文综述了基因治疗在新生血管性年龄相关性黄斑变性(nAMD)等视网膜疾病中的背景、病理生理机制、技术、局限性与未来方向。作者利用腺相关病毒(AAV)载体开发了降低血管内皮生长因子(VEGF)表达的基因治疗,以及同时下调VEGF和上调色素上皮衍生因子(PEDF)的多基因治疗。文章建议这种多靶点基因治疗可能被纳入未来复杂机制视网膜疾病的治疗,并指出需要临床研究来识别可从基因治疗中获益的患者。

要点

  • 抗VEGF治疗需反复玻璃体腔注射且反应不一,基因治疗可能成为减少干预次数的替代方案。
  • 作者开发了AAV载体介导的降低VEGF表达及同时下调VEGF、上调PEDF的多基因治疗。
  • 多靶点基因治疗可能适用于干性AMD伴地图样萎缩、糖尿病黄斑水肿和视网膜静脉阻塞等复杂疾病。

核心结论

  • 多靶点基因治疗可能被纳入未来机制复杂且不能归因于单一介质的视网膜疾病的治疗。
  • 基因治疗预计对需要多次玻璃体腔注射且治疗反应不足的患者最为有益。
  • 在基础研究的同时,需要临床研究来识别在诊断时即可从基因治疗中获益的患者因素。

研究设计与样本

  • 本文为综述,回顾了针对获得性和衰老性视网膜疾病中参与化合物合成的基因治疗的背景、病理生理机制、技术、局限性和未来方向。

主要发现

  • 作者利用腺相关病毒(AAV)载体开发了降低血管内皮生长因子(VEGF)表达的基因治疗。
  • 作者开发了同时下调VEGF合成和上调色素上皮衍生因子(PEDF)合成的多基因治疗。

临床怎么用

  • 作者认为多靶点基因治疗可能被纳入未来干性AMD伴地图样萎缩、糖尿病黄斑水肿和视网膜静脉阻塞等疾病的治疗。
  • 作者认为基因治疗预计对需要多次玻璃体腔注射且治疗反应不足的患者最为有益。
  • 作者结论指出需要临床研究来识别在诊断时即可从基因治疗中获益的患者因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anti-vascular endothelial growth factor (VEGF) therapies have revolutionized the treatment of neovascular age-related macular degeneration (nAMD) and other retinal diseases. However, the necessity for repeated intravitreal injections and the observation of variable treatment responses calls for new treatment modalities where fewer and more effective interventions can result in a clinical effect. Gene therapy might be such an alternative, and therefore the development and clinical application of gene therapy aimed at modifying gene expression has received considerable attention. The article reviews current knowledge of the background, pathophysiological mechanisms, technologies, limitations, and future directions for gene therapy aimed at modifying the synthesis of compounds involved in acquired and senescent retinal disease. The authors have contributed to the field by developing gene therapy to reduce the expression of vascular endothelial growth factor (VEGF), as well as multiple gene therapy for simultaneous downregulation of the synthesis of VEGF and upregulation of pigment epithelium-derived factor (PEDF) using adeno-associated virus (AAV) vectors. It is suggested that such multi-target gene therapy might be included in future treatments of retinal diseases where the underlying mechanisms are complex and cannot be attributed to one specific mediator. Such diseases might include dry AMD (dAMD) with geographic atrophy, but also diabetic macular edema (DME) and retinal vein occlusion (RVO). Gene therapy can be expected to be most beneficial for the patients in need of multiple intra-vitreal injections and in whom the therapeutic response is insufficient. It is concluded, that in parallel with basic research, there is a need for clinical studies aimed at identifying factors that can be used to identify patients who will benefit from gene therapy already at the time of diagnosis of the retinal disease.

来源:Prog Retin Eye Res,查看原文。版权归原作者所有。

引用

  1. Corydon TJ, Bek T. Multiple gene therapy as a tool for regulating the expression of molecules involved in neovascular age-related macular degeneration. Prog Retin Eye Res. 2024. PMID: 39672501. doi:10.1016/j.preteyeres.2024.101323

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。